SAN DIEGO – Early data on an antibody-drug conjugate (ADC) under development at Immunogen Inc. drew attention during the American Society of Hematology (ASH) Annual Meeting and Exposition for its potential meaning to Jazz Pharmaceuticals plc, which has an option on the candidate and two other Immunogen ADC programs.